Uptake of evidence-based statin therapy among atrial brillation patients in China: a report from the CAFR (Chinese Atrial Fibrillation Registry) Study. Int J Cardiol. 2016;220: 284-289. 27. Huisman MV, Ma CS, Diener HC, et al. Antithrombotic therapy use in patients with atrial brillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long- Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Europace. 2016;18(9): 1308-1318. 28. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for re ning stroke risk strati cation in low-risk Asian patients with atrial brillation. J Am Coll Cardiol. 2014;64(16):1658-1665. 29. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial brillation in Hong Kong. Heart Rhythm. 2014;11(8):1401-1408. 30. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial brillation management: a prospective survey in ESC member countries. Eur Heart J. 2005;26(22):2422-2434. 31. Le Heuzey JY, Breithardt G, Camm J, et al. The RecordAF study: design, baseline data, and pro le of patients according to chosen treatment strategy for atrial brillation. Am J Cardiol. 2010;105(5): 687-693. 32. Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for management of atrial brillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2013;165(4):622-629. 33. Lip GYH, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial brillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308-319. 34. Kirchhof P, Ammentorp B, Darius H, et al. 